ASML vs EXOD

ASML exhibits strong financial health with a Piotroski F-Score of 4/9, indicating stable fundamentals despite not reaching the 'strong' threshold. The company's robust profitability metrics—especially a 50.46% ROE and 29.42% profit margin—underscore its operational excellence. While the current price of $1,345.69 trades at a premium to both the Graham Number ($193.99) and Intrinsic Value ($507.83), this is justified by exceptional growth prospects and dominant market positioning in semiconductor equipment. The recent earnings beat rate of 50% over the last four quarters and consistent positive surprises support a bullish outlook. The absence of an Altman Z-Score does not indicate distress risk, as the company maintains a low debt-to-equity ratio (0.24) and strong liquidity. Price trades at a 28.2% premium to fair value estimate ($1050.00), limiting near-term upside from a valuation perspective.

EXOD exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total failure across all fundamental health benchmarks. The company is suffering from a severe revenue collapse, with YoY growth at -34.40% and Q/Q growth at -36.16%, coupled with negative operating margins of -32.33%. While the current ratio of 13.49 suggests high short-term liquidity, the massive 81.9% one-year price decline and bearish insider sentiment signal a lack of confidence in the business model's sustainability. The stock is currently trading near its book value (P/B 0.98), but the lack of earnings growth makes this a value trap rather than a bargain.